Literature DB >> 11606078

Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer.

M Schindl1, P Birner, G Breitenecker, G Oberhuber.   

Abstract

OBJECTIVES: The aim of this study was to investigate the impact of downregulation of KAI1 metastasis suppressor protein in epithelial ovarian cancer. In addition, correlation of KAI1 and p53 immunostaining was investigated.
METHODS: Expression of KAI1 and p53 was immunohistochemically determined in 107 specimens of epithelial ovarian cancer stages I-IV. Survival of patients was investigated using uni- and multivariate analysis.
RESULTS: Strong KAI1 expression was observed in 17.8% of cases, moderate in 27.1%, weak in 21.5%, and complete loss of KAI1 expression in 33.6%. Overexpression of p53 protein was observed in 45.8%. There was correlation of KAI1 expression neither with p53 expression nor with various clinical and histopathological parameters. Serous ovarian cancers showed significantly decreased staining intensity of KAI when compared to other histological types (P = 0.007). Univariate and multivariate analysis revealed that patients with strong or moderate expression of KAI1 had a significantly longer overall (P = 0.0013) and disease-free survival (P = 0.0048) when compared to those with low or absent expression.
CONCLUSION: KAI1 downregulation is an independent prognostic factor in epithelial ovarian cancer, indicating dismal prognosis. Our study did not reveal a correlation between p53 status and KAI1 expression, suggesting that p53-independent mechanisms might be involved in the downregulation of KAI1. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606078     DOI: 10.1006/gyno.2001.6366

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Metastasis-suppressor genes in clinical practice: lost in translation?

Authors:  Alexander N Shoushtari; Russell Z Szmulewitz; Carrie W Rinker-Schaeffer
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

Review 2.  Metastasis suppressor genes.

Authors:  Jinchun Yan; Qin Yang; Qihong Huang
Journal:  Histol Histopathol       Date:  2013-03       Impact factor: 2.303

3.  Normal viability of Kai1/Cd82 deficient mice.

Authors:  John I Risinger; Mary Custer; Lionel Feigenbaum; R Mark Simpson; Shelley B Hoover; Joshua D Webster; Gadisetti V R Chandramouli; Lino Tessarollo; J Carl Barrett
Journal:  Mol Carcinog       Date:  2013-02-08       Impact factor: 4.784

Review 4.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

5.  Intravenous KITENIN shRNA injection suppresses hepatic metastasis and recurrence of colon cancer in an orthotopic mouse model.

Authors:  Jun-Eul Hwang; Hyun-Jeong Shim; Young-Kyu Park; Sang-Hee Cho; Woo-Kyun Bae; Dae-Eun Kim; Kyung-Keun Kim; Ik-Joo Chung
Journal:  J Korean Med Sci       Date:  2011-10-27       Impact factor: 2.153

6.  Prognostic role of CD82/KAI1 in multiple human malignant neoplasms: a meta-analysis of 31 studies.

Authors:  Jundong Zhu; Chenkui Miao; Shouyong Liu; Ye Tian; Chao Zhang; Chao Liang; Aiming Xu; Qiang Cao; Zengjun Wang
Journal:  Onco Targets Ther       Date:  2017-12-06       Impact factor: 4.147

7.  The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.

Authors:  J Markowska; J Bar; R Mądry; I Słomska; M Mardas; J P Grabowski
Journal:  Arch Gynecol Obstet       Date:  2013-04-04       Impact factor: 2.344

8.  EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance.

Authors:  Zehra Tavsan; Hülya Ayar Kayalı
Journal:  Cell Adh Migr       Date:  2020-12       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.